← Leaderboards
Catherine Elizabeth Newman
Harvard Medical School
$129,370
Attributed
$129,370
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $52.7K · FY2021–23$100K$75K$50K$25K$0
'21
'22
'23
Funding mix
By agency
NIH$129,370 · 1
By mechanism
F30$129,370 · 1
Top collaborators
No co-investigators on record.
Most similar at Harvard Medical School
Same institution · by research overlap
- Gary I Yellen$24,659,038
- Marcia Haigis$12,366,449
- Gerhard Wagner$49,510,293
- Nurunisa Akyuz$647,405
- Hao Wu$47,906,316
Others in their field
Other Emerging Leaders on “Clinical Oncology”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$65,477,924
- Martha Hering · Westat, Inc.$57,098,843
- Chris Karlovich · Leidos Biomedical Research, Inc.$38,534,220
- Claudia Valmonte · The Emmes Company, Llc$37,865,589
- Jennifer Marie Suga · Kaiser Foundation Research Institute$32,396,809
- Gregg Kravatz$29,338,050
Research focus
Clinical OncologyCombatApoptosisBax GeneApoptosis Regulation GeneBcl2 GeneBh3 DomainApoptoticBinding SitesBiochemicalBiochemistryBiologyBiophysicsCancer BiologyCancer CellCell DeathBindingCellsCell SurvivalCellular BiologyCessation Of LifeChemoresistanceChemotherapyComparative
Grant awards (3)
Dissecting the Execution Phase of BAK-Mediated Apoptosis in Cancer$52,694
F30 · FY2023 · CA · contact PI
Dissecting the Execution Phase of BAK-Mediated Apoptosis in Cancer$38,696
F30 · FY2022 · CA · contact PI
Dissecting the Execution Phase of BAK-Mediated Apoptosis in Cancer$37,980
F30 · FY2021 · CA · contact PI